94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1554207
The Efficacy and Safety of Ginkgo Terpene Lactone Preparations combined with Antiplatelet Aents in the Treatment of Ischemic Stroke: A Systematic Review and Meta-Analysis
Provisionally accepted- 1 Department of Pharmacy, Second People’s Hospital of Yibin, Yibin, China
- 2 Department of Pharmacy, Yibin Third People's Hospital, Yibin, Sichuan Province, China
- 3 Pharmacy of Department, Second People’s Hospital of Yibin, Yibin, China
Background: This meta-analysis aimed to assess the efficacy and safety of ginkgo terpene lactone preparations including diterpene ginkgolides meglumine injection(DGMI) and ginkgolide injection combined with antiplatelet drugs in the treatment of ischemic stroke.: We systematically searched the randomized controlled trials(RCTs) with publication date earlier than 6 November 2024 in PubMed, China National Knowledge Infrastructure(CNKI), Chinese Science and Technology Journal Database(VIP), Chinese Biomedical Literature Database(CBM), Wanfang Database, Embase, Web of Science, ClinicalTrials.gov, and Cochrane Library. Studies were screened according to inclusion and exclusion criteria, evaluated according to criteria recommended by the Cochrane Handbook, and data were then analyzed using Stata 17 software. Results: Of 1079 identified studies, 27 were eligible and included in our analysis(N = 3336 patients).The meta-analysis demonstrated that the overall response rate [RR = 1.22, 95% CI(1.17, 1.27), Z = 9.76, p < 0.01], as well as the National Institutes of Health Stroke Scale(NIHSS) score and barthel index, were significantly better in the DGMI combined treatment group compared to the antiplatelet therapy alone group. However, there was no significant difference observed between the experimental group and the control group regarding improvements in prognosis and platelet function.The studies included in the analysis reported a total of 419 adverse reactions(ADRs), with 206 occurring in the DGMI combined treatment group; furthermore, there was no significant difference in the incidence of adverse events between the two groups.Ginkgo terpene lactone preparations, when combined with antiplatelet drugs, can significantly enhance the clinical efficacy of ischemic stroke and demonstrate a favorable safety profile.This combination is a potential treatment strategy that can improve the management of IS patients and has high clinical application value.
Keywords: ischemic stroke, DGMI, Ginkgolide Injection, Antiplatelet drugs, Meta-analysis
Received: 01 Jan 2025; Accepted: 03 Mar 2025.
Copyright: © 2025 Xu, Zeng, Liao, Li and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hong Xu, Department of Pharmacy, Second People’s Hospital of Yibin, Yibin, 644000, China
Yan Tang, Pharmacy of Department, Second People’s Hospital of Yibin, Yibin, 644000, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.